; incentives. Sec. 4122. Additional manufacturer reporting requirements in response to drug shortages. Sec. 4123. GAO report on intra-agency coordination. Sec. 4124. Report. Sec. 4125. Safe harbor provision. PART IV—Preventing essential medical device shortages Sec. 4131. Discontinuance or interruption in the production of medical devices. Sec. 4132. GAO report on intra-agency coordination. PART V—Emergency use of laboratory developed tests Sec. 4141. Emergency use of laboratory developed tests. Subtitle B—Access to health care for COVID-19 patients PART I—Coverage of testing and preventive services Sec. 4201. Coverage of diagnostic testing for COVID-19. Sec. 4202. Pricing of diagnostic testing. Sec. 4203. Rapid coverage of preventive services and vaccines for coronavirus. PART II—Support for health care providers Sec. 4211. Supplemental awards for health centers. Sec. 4212. Allowing permanent direct hire of NDMS health care professionals. Sec. 4213. Telehealth network and telehealth resource centers grant programs. Sec. 4214. Rural health care services outreach, rural health network development, and small health care provider quality improvement grant programs. Sec. 4215. United States Public Health Service Modernization. Sec. 4216. Limitation on liability for volunteer health care professionals during covid-19 emergency response. PART III—Miscellaneous provisions Sec. 4221. Confidentiality and disclosure of records relating to substance use disorder. Sec. 4222. Nutrition services. Sec. 4223. Guidance on protected health information. Sec. 4224. Reauthorization of healthy start program. Subtitle C—Innovation Sec. 4301. Removing the cap on OTA. Sec. 4302. Extending the priority review program for agents that present national security threats. Sec. 4303. Priority zoonotic animal drugs. Subtitle D—Finance Committee Sec. 4401. Exemption for telehealth services. Sec. 4402. Inclusion of certain over-the-counter medical products as qualified medical expenses. Sec. 4403. Treatment of direct primary care service